Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6608904 | 0.73 | GALR1 (0.43) | ALDH1A1 | |
| SCHEMBL5550316 | 0.73 | GALR1 (0.43) | ALDH1A1 | |
| SCHEMBL4832705 | 0.73 | KDM4E (0.41) | KDM4EALDH1A1HSD17B10HPGDPOLB | |
| SCHEMBL6861989 | 0.72 | L3MBTL1 (0.45) | KDM4EALDH1A1TSHRLMNAJAK2 | |
| SCHEMBL6609097 | 0.66 | MEN1 (0.32) | CTSLKDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL17220003 | 0.65 | DHFR (0.39) | ALDH1A1MEN1KMT2AHSP90AA1TSHR | |
| SCHEMBL6231144 | 0.63 | SIGMAR1 (0.31) | KDM4EALDH1A1HSD17B10HPGDPOLB | |
| SCHEMBL5552440 | 0.63 | PIM1 (0.43) | KDM4EALDH1A1HSD17B10HPGDPOLB | |
| SCHEMBL17220329 | 0.62 | MAPT (0.45) | CTSLALDH1A1TSHRLMNANPSR1 | |
| SCHEMBL4836067 | 0.61 | GALR1 (0.43) | KDM4EALDH1A1HSD17B10HPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077648-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2004-04-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077648-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | CTSL 2846/4885KDM4E 3314/4885ALDH1A1 4407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.